References
- Psychogios N , HauDD, PengJet al. The human serum metabolome. PLoS One6, e16957 (2011).
- Joyner MJ , PedersenBK. Ten questions about systems biology. J. Physiol. 589, 1017–30 (2011).
- Henry H , SobhiHR, ScheibnerO, BromirskiM, NimkarSB, RochatB. Comparison between a high-resolution single-stage Orbitrap and a triple quadrupole mass spectrometer for quantitative analyses of drugs. Rapid Commun. Mass Spectrom. 26, 499–509 (2012).
- Ramanathan R , KorfmacherW. The emergence of high-resolution MS as the premier analytical tool in the pharmaceutical bioanalysis arena. Bioanalysis4, 467–469 (2012).
- Rochat B , KottelatE, McMullenJ. The future key role of LC–high-resolution-MS analyses in clinical laboratories: a focus on quantification. Bioanalysis4, 2939–2958 (2012).
- Dunn WB , BroadhurstD, BegleyPet al. Human serum metabolome (HUSERMET) consortium. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat. Protoc. 6, 1060–1083 (2011).
- Yuan M , BreitkopfSB, YangX, AsaraJM. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 7, 872–881 (2012).
- Vuckovic D . Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry. Anal. Bioanal. Chem. 403, 1523–1548 (2012).
- Gika HG , TheodoridisGA, VrhovsekU, MattiviF. Quantitative profiling of polar primary metabolites using hydrophilic interaction ultrahigh performance liquid chromatography–tandem mass spectrometry. J. Chromatogr. A1259, 121–127 (2012).
- Dumlao DS , BuczynskiMW, NorrisPC, HarkewiczR, DennisEA. High-throughput lipidomic analysis of fatty acid derived eicosanoids and N-acylethanolamines. Biochim. Biophys. Acta. 1811, 724–736 (2011).
- Nicholls AW . Realising the potential of metabolomics. Bioanalysis4, 2195–2197 (2012).
- Dunn WB , BroadhurstD, BrownMet al. Metabolic profiling of serum using ultra performance liquid chromatography and the LTQ-Orbitrap mass spectrometry system. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 871, 288–98 (2008).
- Nicholson G , RantalainenM, MaherADet al. Human metabolic profiles are stably controlled by genetic and environmental variation. Mol. Syst. Biol. 7, 525 (2011).
- Plebani M , LippiG. Personalized (laboratory) medicine: a bridge to the future. Clin. Chem. Lab. Med. 6, 1–4 (2013).
- Sottas PE , KapkeGF, VesterqvistO, LerouxJM. Patient-specific measures of a biomarker for the generation of individual reference intervals: hemoglobin as example. Transl. Res. 158, 360–368 (2011).
- Sottas PE , VernecA. Current implementation and future of the Athlete Biological Passport. Bioanalysis4, 1645–1652 (2012).
- Sottas PE , KapkeGF, LerouxJM. Adaptive bayesian approach to clinical trial renal impairment biomarker signal from urea and creatinine. Int. J. Biol. Sci. 9, 156–163 (2013).
- Adamski J , SuhreK. Metabolomics platforms for genome wide association studies-linking the genome to the metabolome. Curr. Opin. Biotechnol. 24, 39–47 (2013).
- Suhre K , ShinSY, PetersenAKet al. Human metabolic individuality in biomedical and pharmaceutical research. Nature477, 54–60 (2011).
- Bellcross CA , PagePZ, Meaney-DelmanD. Direct-to-consumer personal genome testing and cancer risk prediction. Cancer J. 18, 293–302 (2012).